BEND4 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HeLa human cervical adenocarcinoma cell line, engineered for targeted disruption of the BEND4 gene. This loss-of-function model enables researchers to investigate the cellular and molecular consequences of BEND4 ablation in a widely used cancer cell context. The polyclonal format provides a heterogeneous pool of edited cells, minimizing clonal artifacts and facilitating robust functional genomics studies.
HeLa cells, the parental line, are an immortalized epithelial cell line originally isolated from a cervical adenocarcinoma patient and contain integrated human papillomavirus 18 (HPV-18) DNA. These cells exhibit rapid proliferation, high invasive potential, and aneuploidy, making them a standard model for cancer biology, HPV-driven oncogenesis, and cell signaling research. Their robust growth and transfectability support efficient CRISPR/Cas9 gene editing and downstream phenotypic analyses.
BEND4 encodes BEN domain-containing protein 4, a putative transcriptional repressor that interacts with corepressor complexes to silence target gene expression. Mechanistically, BEND4 is thought to recruit HDAC1/2 and CoREST, along with SIN3A, to specific genomic loci, thereby catalyzing histone deacetylation and chromatin compaction. Upstream, BEND4 may be regulated by the RE1-silencing transcription factor (REST/NRSF), linking it to neuronal gene programs, though its downstream targets in HeLa cells remain largely undefined but could encompass genes involved in proliferation and apoptosis.
In the HeLa cellular environment, which is driven by HPV18 E6 and E7 oncoproteins, disruption of BEND4 provides a unique system to explore its potential role in cervical cancer pathogenesis. BEND4 is silenced by promoter methylation in several cancers, suggesting a tumor-suppressive function that can be interrogated using this knockout model. Loss of BEND4 may de-repress growth-regulatory genes, offering insights into epigenetic mechanisms underlying unchecked cell division and survival in HPV-positive carcinomas.
This product is ideally suited for a broad range of experiments, including RT-qPCR and Western blotting to confirm knockout, proliferation assays (MTT or BrdU), apoptosis detection (Annexin V staining), and RNA-seq transcriptome profiling to identify differentially expressed genes. Chromatin immunoprecipitation (ChIP) can assess histone modification changes at target promoters, while reporter assays gauge alterations in transcriptional activity. Flow cytometry enables detailed cell cycle analysis. Collectively, these applications support drug target validation, epigenetic research, and functional interrogation of BEND4??s tumor-suppressive role. For additional technical information or to order, please contact Ascent Research.
